SectorBiological Technology
Established Date01/12/2017
Listing Date04/02/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees29
Fiscal Year Ends31/12
Security TypeCommon stock
Office address1405 Research Blvd, Suite 125, Rockville, MD 20850
Business
IntroductionSensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, was incorporated in Delaware on December 1, 2017. The company is an immuno-oncology company focused on the discovery and development of next-generation therapies for cancer patients. Through the TMAb (Tumor Microenvironment Activating Biologics) platform, the Company is developing highly selective therapies designed to selectively disable immunosuppressive signals or activate immune stimulating signals in the tumor microenvironment to release T cells against tumors.
